【摘要】 不同作用机制的口服降糖药联合治疗2型糖尿病在临床应用中已十分广泛,其中二甲双胍联合吡格列酮是中华医学会糖尿病学分会、美国糖尿病协会等国内外指南推荐的首选治疗方案之一。吡格列酮二甲双胍片作为二者的固定复方制剂,具有经济方便的优点,同时提高了患者的用药依从性。临床应用时可根据患者的具体情况单独使用吡格列酮二甲双胍片,或与其他多种口服降糖药联合用药。为提高临床医生对此类单片复方制剂的认识,促进基层治疗的合理用药,根据现有的循证证据,制定了《吡格列酮二甲双胍复方制剂临床应用专家建议》,分别从临床地位、作用机制、疗效、安全、推荐人群和特殊人群等方面进行阐述。更多还原

【Abstract】 It is more and more common in clinical practice to use combination therapy(first-line plus second line and or third line hypoglycemic agents) for the treatment of type 2 diabetes. Metformin combined Pioglitazone is a recommended combination by the Chinese Diabetes Society and American Diabetes Association and other organization like International Diabetes Federation guideline in treatment of type 2 diabetes. The fixeddose combination(FDC) of Pioglitazone and Metformin may increase patients’ medication compliance. Pioglitazone and Metformin tablets can be used alone, or be combined with other hypoglycemic agents in clinical practice. In order to help clinicians to know well FDC, here we draw up this recommendation based on the evidence of efficacy, safety, indications and side effects for Pioglitazone and Metformin combination.更多还原